Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

 Key Statistics

Ownership: Public

Web Site: Ariad
Symbol: ARIA

 Company News
Ariad (ARIA) Announces Data Presentations At The European Hematology Association Congress 5/22/2015 6:39:44 AM
Ariad (ARIA) To Present At The Jefferies and Co. 2015 Global Healthcare Conference 5/21/2015 12:01:30 PM
Ariad (ARIA) Announces Data Presentations At The 2015 ASCO Annual Meeting 5/14/2015 12:28:03 PM
Ariad (ARIA) Reports First Quarter 2015 Financial Results And Progress On Strategic Objectives 5/7/2015 12:55:03 PM
Ariad (ARIA) Announces Commercial Distribution Agreement For Iclusig (ponatinib) In Turkey 5/6/2015 11:39:22 AM
Outgoing Ariad (ARIA) CEO Has No Regrets and "Will Work Harder Than Ever" Until a Successor is Named 4/30/2015 6:20:45 AM
Ariad (ARIA) CEO Leaves Amid Proxy Battle with Hedge Fund Sarissa, Inc. 4/29/2015 5:55:51 AM
Ariad (ARIA) To Webcast Conference Call On First Quarter 2015 Financial Results 4/23/2015 10:15:55 AM
Ariad (ARIA) Announces Issuance Of Key U.S. Patent On Brigatinib 4/22/2015 10:40:14 AM
Why Ariad (ARIA) Could Be Worth $3 Billion to a Big Drugmaker 4/22/2015 6:05:45 AM